Alzamend Neuro Management
Management criteria checks 3/4
Alzamend Neuro's CEO is Stephan Jackman, appointed in Nov 2018, has a tenure of 7.67 years. total yearly compensation is $468.29K, comprised of 74.7% salary and 25.3% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth $38.40. The average tenure of the management team and the board of directors is 7.2 years and 5.1 years respectively.
Key information
Stephan Jackman
Chief executive officer
US$468.3k
Total compensation
| CEO salary percentage | 74.74% |
| CEO tenure | 7.7yrs |
| CEO ownership | 0.0009% |
| Management average tenure | 7.2yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges
Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial
Alzamend Neuro (NASDAQ:ALZN) said it began dosing healthy people in a phase 2A study of oral drug AL001 treat people with dementia related to Alzheimer’s. The placebo-controlled trial (AL001-02) started in May to evaluate the safety and tolerability of AL001 under multiple-dose setting, to determine the maximum tolerated dose, the company said in an Oct. 5 press release. Based on a recommendation by the U.S. Food and Drug Administration (FDA) after its review on Alzamend's pre-investigational new drug briefing package to develop AL001 for bipolar, major depressive and post-traumatic stress disorders, the ongoing clinical trial in Alzheimer's patients was expanded, the company added. ALZN -6.52% to $1.29 premarket Oct. 5Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia
Clinical-stage biopharma Alzamend Neuro (NASDAQ:ALZN) on Thursday said it had submitted an investigational new drug (IND) application to the U.S. FDA for a phase 1/2A trial of its immunotherapy product candidate ALZN002 for the treatment of dementia of the Alzheimer's type. ALZN said the product candidate consists of dendritic cells, or activated white blood cells taken from an individual patients so that they can be engineered outside of the body to attack Alzheimer's-related amyloid-beta proteins. The purpose of the phase 1/2A trial would be to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared to placebo in 20‑30 subjects with mild to moderate dementia of the Alzheimer’s type, ALZN said in a statement. ALZN stock -1.7% to $1.16 in premarket trading. Shares of ALZN gained 6.3% on Wednesday, amidst a broader rally in drug companies that are working on Alzheimer's treatments sparked by positive data from Biogen (BIIB) and Eisai (OTCPK:ESALY).Alzamend Neuro receives positive pre-IND response from FDA for AL001
Alzamend Neuro (NASDAQ:ALZN) said on Monday it had received a written response to its meeting request relating to its Type B Pre-Investigational New Drug application from the U.S. Food and Drug Administration. The company said the FDA’s response provides a path for its planned clinical development of AL001 for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder. AL001 has the potential to deliver benefits of marketed lithium carbonate while avoiding current toxicities associated with lithium. Alzamend expects to file INDs for bipolar disorder, MDD and PTSD upon the completion of the current Phase IIA multiple ascending dose study.Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease. The phase 2 multiple ascending dose study using AL001 treating this patient population is expected to begin Q2 of 2022. AL002 is another shot on goal targeting Alzheimer's Disease and it is a cell therapy focused on boosting T-cell activity in the body to clear amyloid from the brain. It is estimated that the global market opportunity for Alzheimer's Disease could reach $25.5 billion by 2025.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jan 31 2026 | n/a | n/a | -US$8m |
| Oct 31 2025 | n/a | n/a | -US$6m |
| Jul 31 2025 | n/a | n/a | -US$7m |
| Apr 30 2025 | US$468k | US$350k | -US$5m |
| Jan 31 2025 | n/a | n/a | -US$4m |
| Oct 31 2024 | n/a | n/a | -US$6m |
| Jul 31 2024 | n/a | n/a | -US$7m |
| Apr 30 2024 | US$444k | US$350k | -US$10m |
| Jan 31 2024 | n/a | n/a | -US$12m |
| Oct 31 2023 | n/a | n/a | -US$15m |
| Jul 31 2023 | n/a | n/a | -US$15m |
| Apr 30 2023 | US$2m | US$300k | -US$15m |
| Jan 31 2023 | n/a | n/a | -US$15m |
| Oct 31 2022 | n/a | n/a | -US$13m |
| Jul 31 2022 | n/a | n/a | -US$13m |
| Apr 30 2022 | US$473k | US$303k | -US$12m |
| Jan 31 2022 | n/a | n/a | -US$10m |
| Oct 31 2021 | n/a | n/a | -US$8m |
| Jul 31 2021 | n/a | n/a | -US$6m |
| Apr 30 2021 | US$225k | US$225k | -US$5m |
| Jan 31 2021 | n/a | n/a | -US$5m |
| Oct 31 2020 | n/a | n/a | -US$5m |
| Jul 31 2020 | n/a | n/a | -US$5m |
| Apr 30 2020 | US$2m | US$188k | -US$4m |
Compensation vs Market: Stephan's total compensation ($USD468.29K) is about average for companies of similar size in the US market ($USD659.85K).
Compensation vs Earnings: Stephan's compensation has increased whilst the company is unprofitable.
CEO
Stephan Jackman (49 yo)
Mr. Stephan Jackman has been Chief Executive Officer of Alzamend Neuro, Inc. since November 20, 2018 and has been its Director since September 2020. Mr. Jackman has experience in administration, business a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.7yrs | US$468.29k | 0.00087% $ 38.4 | |
| Founder & Vice Chairman | 2.5yrs | US$25.00k | no data | |
| Chief Financial Officer | 4.9yrs | US$150.00k | 0.016% $ 713.2 | |
| Executive VP | 7.2yrs | US$50.00k | 0% $ 0 | |
| Senior Vice President of Finance | 5.1yrs | no data | 0% $ 0 |
Experienced Management: ALZN's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$468.29k | 0.00087% $ 38.4 | |
| Founder & Vice Chairman | 2.5yrs | US$25.00k | no data | |
| Executive VP | 5.8yrs | US$50.00k | 0% $ 0 | |
| Independent Chairman of Board | 10.1yrs | US$50.00k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$25.00k | 0.0012% $ 51.2 | |
| Independent Director | 5.1yrs | US$25.00k | 0.00066% $ 29.1 | |
| Member of Scientific Advisory Board | 7yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.1yrs | US$25.00k | 0.0019% $ 85.6 | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data |
Experienced Board: ALZN's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 23:19 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/01/31 |
| Annual Earnings | 2025/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alzamend Neuro, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |